Multicenter study reveals poor prognosis associated with MRD positivity in adverse-risk AML transplantation, highlighting the need for refined post-remission monitoring.
Acute myeloid leukemia (AML) is a highly heterogeneous disease distinguished by different cytogenetic and genetic characteristics [ 1 , 2 ]. Currently, the risk classification based on the cytogenetics and molecular markers (e.g., the European LeukemiaNet [ELN] risk stratification) is the mainstay criterion that direct the treatments of adult AML patients, and those with adverse-risk AML are recommended to receive allogeneic hematopoietic stem cell transplantation (allo-HSCT) in their first complete remission (CR1) [ 1 , 3 ]. Several studies have reported that the efficacy of allo-HSCT is superior to that of those receiving consolidation chemotherapy alone in adverse-risk AML patients and the benefit of allo-HSCT is observed across ages and donor type [ 4 ].
No takes yet. Share an insight, caveat, or question.
Cao et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: